Vetbiobank develops neonatal stem cell-based cellular drugs with unique potential to fight dogs, cats and horses' chronic inflammatory diseases. Whether they are sick, injured or just old, they help restore their quality of life and well-being.
You are a French speaking practioner? Discover the latest information on our products in development
Vetbiobank deploys its intellectual property protection strategy internationally and expands its patent portfolio with: A regional phase covering high-potential geographical areas and an additional international PCT filing.Â
Read moreOur new website is online, we invite you to surf on our internet site and discover Vetbiobank's expertise in cell therapy for animal health.
Read morePionnier de la me?decine re?ge?ne?rative ve?te?rinaire, la jeune pousse en voie de diversification est en phase de leve?e de fonds pour financer ses e?tudes cliniques et?
Read more
Virtual Event
22-23 February,2021
Animal Health Innovation Europe is the leading investment forum for the animal health sector in Europe. It presents the most interesting innovations in the field of animal health and nutrition.
Vetbiobank has been selected to present at the Innovation Show Case session.
Come and meet Vetbiobank's management team
To develop cellular therapies for veterinary use, to improve and lighten the management of chronic inflammatory animal diseases.
Then to produce them industrially in order to make them accessible to as many people as possible.
Thanks to their intact biological potential linked to their youth, neonatal stem cells can act on the causes responsible for many chronic inflammatory diseases affecting the joints, digestive system, skin, and mucous membranes of animals.
Vetbiobank develops its therapeutic innovations in order to bring:
– to animals, treatments that allow
– to pet owners, a solution
– to veterinarians, a comlementary expertise
Company
Technologies
Products
Partners
News
© 2021 Vetbiobank All Rights Reserved
Ask your veterinarian for the price of a stem cell injection at his clinic.
| Range | Product | Development & optimization | Proof of Concept | Pilot study |
Industrialisation / Manufacturing |
Pivotal study | Approval | Marketing Launch |
|---|---|---|---|---|---|---|---|---|
|
CANIPREN
|
VBX-01 |
|
|
|
|
|
|
|
|
CA0102 |
|
|
|
|
|
|
|
|
|
CA0103 |
|
|
|
|
|
|
|
| Range | Product | Development & optimization | Proof of Concept | Pilot study |
Industrialisation / Manufacturing |
Pivotal study | Approval | Marketing Launch |
|---|---|---|---|---|---|---|---|---|
|
FELIPREN
|
FE0101 |
|
|
|
|
|
|
|
|
FE0102 Chronic kidney failure |
|
|
|
|
|
|
|
|
|
FE0103 |
|
|
|
|
|
|
|
| Range | Product | Development & optimization | Proof of Concept | Pilot study |
Industrialisation / Manufacturing |
Pivotal study | Approval | Marketing Launch |
|---|---|---|---|---|---|---|---|---|
|
EQUIPREN
|
EQ0101 |
|
|
|
|
|
|
|
